Licensing Opportunities

A A A

Office of Technology Transfer 

Details

Project TitleCombination Therapy for Cancer: Oral Fenretinide and Ketoconazole
Track Code2007-012
Short DescriptionTech Summary: This invention combines fenretinide with metabolic degradation inhibitors of fenretinide to increase the therapeutic effect of fenretinide as an anti-cancer drug.
Abstract

Background: Oral Fenretinide (4-hydroxy(phenyl) retinamide), a synthetic retinoid derivative which has been investigated for potential use in the treatment of cancer and some other diseases.

Sub-optimal bioavailability of traditional fenretinide formulations has been a limitation for achieving high efficacy.


Technology Description: 
This invention uses metabolic degradation inhibitors of fenretinide to increase the plasma and tissue levels of fenretinide.

The preliminary data show that ketoconazole, a fenretinide degradation inhibitor, has singular effect in increasing the fenretinide bioavailability and efficacy.

Our pre-clinical data in multiple tumor xenograft models demonstrate the usefulness of this combination as an effective way to improve fenretinide’s therapeutic potential as an anti-cancer agent.


Applications: Cancer treatment

Advantages: 

  • Orally administered
  • Improved bioavailability
  • Improved anti-tumor activity of fenretinide

Development Stage: Pre-clinical proof of principle data.


IP Protection: PCT application filed PCT/US2008/011207

 
Tagsinhibitors, fenretinide, retinoid acid, retinoid acid derivatives, anticancer agents, anti-cancer, anticancer, anti-cancer therapy, therapy, solid tumor, tumor treatments, oncology drugs, oncology, drug formulation, therapeutic compound, therapeutic agents, therapeutic
 
Posted DateOct 26, 2010 5:29 PM

Researcher

Name
Barry J Maurer
C. Patrick Reynolds

Intellectual Property

Patent Number Issue Date Type Country of Filing
PCT/US2008/011207 Sep 26, 2008 Other Patent United States